Innoviva, Inc., 10% Owner at Entasis Therapeutics Holdings Inc. (ETTX), bought 9,345,794 shares at $2.68 ($25.0M) on 2020-09-01, disclosed to the SEC on 2020-09-01.
Open-market purchase of $25.0M ETTX by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.68 | 4,672,897 | $12.5M | 50.0% |
| 2 | $2.68 | 4,672,897 | $12.5M | 50.0% |
| Total | $2.68 avg | 9,345,794 | $25.0M | 100% |
| Filing → |
| ARMP | BUY | 2021-03-17 | $27.9M | — | Filing → |
| ETTX | BUY | 2020-06-12 | $31.7M | — | Filing → |
| ARMP | BUY | 2020-03-31 | $44.3M | — | Filing → |